The firm said it would focus resources on other late-stage programs after a Phase III study showed little survival benefit on first-line bemarituzumab.

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

The firm is expecting a preliminary data read out from the trial, which is already underway in the US, in the second half of this year.

It will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...